

Center for Vaccine  
Ethics and Policy



**Vaccines and Global Health: The Week in Review**  
**01 July 2023 :: Issue 709**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director*

*Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

***Contents [click to move among sections]***

*:: [Organization Announcements](#)*

*:: [Journal Watch](#)*

*:: [Pre-Print Servers](#)*

## Milestones, Perspectives

.....  
.....

### **TB Vaccine**

#### **[Wellcome and the Gates Foundation to Fund Late-Stage Development of a Tuberculosis Vaccine Candidate That Could Be the First in 100 Years If Proven Effective](#)**

*TB is one of the world's deadliest diseases, killing about 4,300 people per day, mostly those living in poverty*

LONDON and SEATTLE (June 28, 2023) – Wellcome and the Bill & Melinda Gates Foundation today announced **funding to advance a tuberculosis (TB) vaccine candidate, M72/AS01E (M72), through a Phase III clinical trial. If proven effective, M72 could potentially become the first new vaccine to help prevent pulmonary TB, a form of active TB, in more than 100 years.**

In 2021, an estimated 10.6 million people fell ill with TB and 1.6 million died—about 4,300 people per day. The disease primarily affects people in low- and middle-income countries, and those at highest risk are often living in poverty, with poor living and working conditions and undernutrition. Up to a quarter of the world's population is thought to have latent TB, a condition in which a person is infected with the bacterium that causes TB but does not have any symptoms and is at risk of progressing to active TB disease...

**To support the M72 Phase III clinical trial, which will cost an estimated US\$550 million, Wellcome is providing up to US\$150 million and the Gates Foundation will fund the remainder, about US\$400 million.**

"TB remains one of the world's deadliest infectious diseases," said Julia Gillard, chair of the Board of Governors at Wellcome. "The development of an affordable, accessible vaccine for adults and adolescents would be game-changing in turning the tide against TB. Philanthropy can be a catalyst to drive progress, as shown by this funding of the M72 vaccine as a potential new tool in preventing escalating infectious diseases to protect those most affected. Sustainable progress against TB and wider disease threats will depend on global collaboration, financial backing, and political will. By working with communities and researchers in countries with a high burden of the disease, we can get one step closer to eliminating TB as a public health threat."

The only TB vaccine in use today, bacille Calmette-Guérin (BCG), was first given to people in 1921. It helps protect babies and young children against severe systemic forms of TB but offers limited protection against pulmonary TB among adolescents and adults.

"With TB cases and deaths on the rise, the need for new tools has never been more urgent," said Bill Gates, co-chair of the Bill & Melinda Gates Foundation. "Greater investment in safe and effective TB vaccines alongside a suite of new diagnostics and treatments could transform TB care for millions of people, saving lives and lowering the burden of this devastating and costly disease."

**Over 25 years, a vaccine with at least 50% efficacy could prevent up to 76 million new TB cases and 8.5 million deaths, avert the need for 42 million courses of antibiotic treatment, and prevent US\$41.5 billion in TB-related catastrophic household costs, especially for the world's poorest and most vulnerable people, according to the World Health Organization (WHO).\***

**The Phase III clinical trial to assess the candidate vaccine's efficacy at preventing progression from latent TB infection to pulmonary TB will be sponsored by the Bill & Melinda Gates Medical Research Institute (the Gates MRI),** a nonprofit organization and subsidiary of the Gates Foundation dedicated to the development and effective use of novel biomedical interventions to address substantial global health concerns. Conducted in collaboration with an international consortium of TB clinical investigators, the trial will enroll approximately 26,000 people, including people living with HIV and without TB infection, at more than 50 trial sites in Africa and Southeast Asia. Additional details about the trial design and participants will be announced by the Gates MRI in the coming months. The Gates MRI is the license holder for M72 in low- and middle-income countries with high TB burden.

**The M72 vaccine candidate, one of 17 TB vaccine candidates currently in the pipeline, has been in development since the early 2000s.** It was developed by **GSK** up to the proof-of-concept phase (Phase IIb), in partnership with **Aeras and the International AIDS Vaccine Initiative (IAVI)**, and was funded in part by the Gates Foundation. In the Phase IIb trial, M72 showed approximately 50% efficacy in reducing pulmonary TB in adults with latent TB infection—an unprecedented result in decades of TB vaccine research...

.....  
.....

## **Gavi**

### **[David Marlow to Become Interim Chief Executive Officer of Gavi](#)**

Geneva, 26 June 2023 – The Gavi Board decided today to appoint David Marlow, currently Gavi's Chief Operating Officer, to the position of Interim Chief Executive Officer, effective 3 August 2023.

The appointment follows a communication from Dr Muhammad Pate, who had been approved by the Gavi Board in February to become Gavi's next CEO, that he will not be able to join Gavi. Dr Pate informed the Gavi Board Chair and Vice Chair that he has taken an incredibly difficult decision to accept a request to return and contribute to his home country, Nigeria.

Gavi fully respects the decision and wishes Dr Pate the very best for the future. On informing Gavi, Dr Pate thanked the Chair of the Gavi Board, José Manuel Barroso, the diverse set of Gavi Board members and partners, current CEO Dr. Seth Berkley, and the Secretariat staff for their support over the last few months, commenting that he will remain a steadfast champion of the Gavi mission.

The Gavi Board is delighted that Mr Marlow has accepted this responsibility and has full confidence in the strength of the Gavi leadership team and the Alliance to support this transition. The Gavi Board is committed to delivering on its mission and strategic priorities while it conducts a search for the next CEO.



## **Global Vaccine Alliance to deploy six-in-one vaccine to lower-income countries, establish innovative mechanisms to protect against future epidemic threats**

- Gavi's Board approved **new investments in six-in-one (hexavalent) vaccine and approved a long list of potential new vaccines for consideration for inclusion in future Gavi programmes** at its Board Meeting, which concluded today
- The Board also **reconfirmed the essential role that Gavi plays in pandemic preparedness, prevention and response** – discussing the progress made on the African Vaccine Manufacturing Accelerator, a financial instrument which aims to support sustainable vaccine manufacturing in Africa, as well as approving pilot investments for investigational candidate vaccines against Marburg and Ebola Sudan if needed for outbreak response, with discussion and potential approval of a broader programme in December 2023.
- Professor José Manuel Barroso, Chair of the Gavi Board: "Gavi's record as an innovator and a disrupter in global health has been confirmed today."

Geneva, 28 June 2023 – The Board of Gavi, the Vaccine Alliance yesterday outlined a set of decisions that will expand the portfolio of vaccine programmes available to lower-income countries in the coming years. It also committed to providing COVID-19 vaccines to high-risk groups until 2025 and approved an innovative plan to enable pilot investment in reserves of investigational candidate vaccines if appropriate candidate vaccines become available, helping respond more quickly to outbreaks of Marburg and Ebola Sudan viruses.

**"Gavi's record as an innovator and a disrupter in global health has been confirmed today," said Professor José Manuel Barroso, Chair of the Gavi board. "Decisions taken by our Board will help countries fight disease more cost-effectively, be better equipped to fight back against emerging threats and continue to protect those most at risk from COVID-19."**

### ***EXPANDING ACCESS TO NEW VACCINES***

When the Alliance was founded in 2000, it supported vaccines against just three diseases; today it supports vaccines against 19. Continuing this trend, this week's Board meeting saw the Alliance discuss and approve plans that will see lower-income countries access new vaccines in the coming years.

**Hexavalent vaccine:** The Board approved Gavi investment in the six-in-one vaccine – a combination of the pentavalent vaccine, which protects against diphtheria, tetanus, pertussis (whooping cough), hepatitis B and Haemophilus influenzae type b, and the inactivated polio vaccine (IPV). A window will now be opened for countries to apply for funding. The hexavalent vaccine is expected to help countries deliver protection against all these diseases more efficiently and cost-effectively, and to contribute significantly to polio eradication efforts by expanding IPV coverage. Gavi and Alliance partners will also provide support to countries who are currently administering pentavalent vaccine and want to make the switch, and work with manufacturers to ensure the health of both the pentavalent and IPV markets.

**COVID-19:** The Gavi Board also confirmed that, as part of the transition from COVAX as an emergency response, Gavi will continue to support countries in their efforts to ensure high-risk groups are protected against COVID-19 in 2024-2025.

**2018 Vaccine Investment Strategy:** Gavi confirmed to the Board today that the Vaccine Alliance will re-start programmes to introduce vaccines that were previously approved but paused either due to the pandemic or product development delays. On this list are hepatitis B birth dose, diphtheria-tetanus-pertussis (DTP) boosters, and rabies post-exposure prophylaxis (PEP). Also included on the 2018 list were two additional vaccines – the maternal respiratory syncytial virus (RSV) vaccine and multivalent meningococcal conjugate vaccine – which could soon see approved products on the market. The next steps in this process are to continue working with Alliance partners, particularly the World Health Organization (WHO), UNICEF and countries to create timelines, technical guidance for introduction of these new products, and outline the parameters of these new programmes.

**2024 Vaccine Investment Strategy:** Looking further ahead, the Board also approved a long list of vaccines to be considered for inclusion in Gavi's next Vaccine Investment Strategy, which will be finalised by 2024. The approved long list includes licensed or pipeline products against hepatitis E, mpox, dengue, COVID-19, tuberculosis, group B streptococcus, chikungunya, and shigella...

.....  
.....  
.....

## ***PHEIC*** **Polio**

### **Polio this week as of 28 June 2023 - GPEI**

#### ***Headlines:***

:: The 2023 Afghanistan National Emergency Action Plan (NEAP) which provides a roadmap of what it will take to stop polio transmission in the country is now available here.

:: GPEI has just released the Global OPV Stockpile Strategy which lays out the strategy for developing and managing the Global OPV Stockpile for the period 2022-2026, in support of and in alignment with the GPEI 2022-2026 strategy.

:: nOPV2 rollout: Approximately 670 million doses of nOPV2 have been administered across 31 countries under its WHO Emergency Use Listing (EUL) to date. An additional 13 countries have met the requirements for nOPV2 use in the event of an outbreak. For more information, visit the nOPV2 webpage.

#### ***Summary of new polioviruses this week:***

:: Côte d'Ivoire: one cVDPV2 positive environmental sample

:: DR Congo: four cVDPV1 and three cVDPV2 cases

:: Madagascar: three cVDPV1 cases and eight cVDPV1 positive environmental samples

:: Nigeria: three cVDPV2 cases

:: Zambia: one cVDPV2 case

.....  
.....

## **Coronavirus [COVID-19]**

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

### ***WHO Weekly Epidemiological and Operational updates***

Last update: **28 June 2023**

**Confirmed cases ::** 767 518 723

**Confirmed deaths ::** 6 947 192

**Vaccine doses administered:** 13 461 751 619

## **Weekly epidemiological update on COVID-19 - 29 June 2023**

### *Overview*

Globally, over one million new cases and over 5700 deaths were reported in the last 28 days (29 May to 25 June 2023). While five WHO regions have reported decreases in both cases and deaths, the African Region has reported a decrease in cases but an increase in deaths. As of 25 June 2023, over 767 million confirmed cases and over 6.9 million deaths have been reported globally. Reported cases are not an accurate representation of infection rates due to the reductions in testing and reporting globally. During this 28-day period, only 62% (146 of 234) of countries and territories reported at least one case – a proportion that has been declining since mid-2022.

.....  
.....

### ***Our World in Data***

#### **Coronavirus (COVID-19) Vaccinations** [Accessed 01 Jul 2023]

:: [70.3%](#) of the world population has received at least one dose of a COVID-19 vaccine.

:: [13.47 billion doses](#) have been administered globally, and [72,697](#) are now administered each day.

:: [32.2%](#) of people in low-income countries have received at least one dose

.....  
.....

## **MPOX**

### **Multi-country outbreak of mpox, External situation report #25 – 24 June 2023**

#### *Highlights*

:: Since the last situation report published on 10 June 2023, and as of 19 June, 114 new confirmed or probable mpox cases and one new death in a confirmed case have been reported to WHO.

:: Virus transmission continues at a low pace in several countries, and the main epidemiological and clinical characteristics of cases are stable over time. Nineteen countries are reporting cases.

.....  
.....

## **UN OCHA – Current Emergencies**

### *Current Corporate Emergencies*

#### **Afghanistan**

##### *Editor's Note:*

*We observe that OCHA has removed Afghanistan from its listing of "Current Emergencies." We did not identify any explanation for its removal.*

#### **Northern Ethiopia**

*No new digest content identified.*

## **Somalia**

*No new digest content identified.*

## **Türkiye/Syria Earthquakes**

26 Jun 2023

**[Today's top news: Syria, Jordan](#)**

## **Ukraine**

*Highlights* Last Updated: 26 May 2023

.....

.....

## **WHO & Regional Offices** [to 01 Jul 2023]

<https://www.who.int/news>

*Selected News/Announcements/Statements*

29 June 2023 Departmental news

**[New report calls for greater attention to children's vital first years](#)**

28 June 2023 Departmental news

**[Improving access to water, sanitation and hygiene can save 1.4 million lives per year, says new WHO report](#)**

28 June 2023 Departmental news

**[WHO publishes information notes on the use of bedaquiline and delamanid in children and adolescents with drug-resistant tuberculosis](#)**

28 June 2023 Departmental news

**[WHO announces the development of a guideline on the health of trans and gender diverse people](#)**

27 June 2023 Departmental news

**[New collaboration between WHO International Classification of Diseases and MedDRA launched](#)**

26 June 2023 Departmental news

**[Supporting vaccinations and strengthening health systems in 16 African countries](#)**

An EU-funded and WHO-implemented project helped health systems become more resilient and better prepared to tackle future epidemics of vaccine-preventable diseases.

COVID-19 vaccination coverage is on the rise in Africa's most fragile humanitarian settings as the two-year project comes to a close.

At the start of 2022, the COVID-19 vaccination rate was less than 5% on average in the participating countries: Burundi, Cameroon, the Central African Republic, Chad, the Democratic Republic of the Congo, Guinea, Liberia, Madagascar, Mali, Mozambique, Niger, Nigeria, Somalia, the South Sudan Republic, Sudan, and Tanzania.

That rate is now closing in on 30% – the continent's average. 34 million people have received the two-dose vaccinations – more than 1 in 4 people across the population of all countries...

26 June 2023 Departmental news

**[Message by the Director of the Department of Immunization, Vaccines and Biologicals at WHO - June 2023](#)**

... The upcoming **release of the WHO/UNICEF estimates of 2022 national immunization coverage (WUENIC 2023) on 18 July 2023**, will be critical to provide the requisite assessments, data and strategies to member states and health partners in ongoing efforts of the Big Catch-up so as to ensure all children and adolescents receive lifesaving vaccinations despite the long-standing and new challenges...

.....

**WHO Regional Offices**

*Selected Press Releases, Announcements*

**WHO African Region**

*No new digest content identified.*

**WHO Region of the Americas** PAHO

:: **[PAHO Executive Committee concludes today with the adoption of 12 resolutions to improve health in the Region of the Americas](#)**

Washington D.C. 29 June 2023 (PAHO/WHO) – The Executive Committee of the Pan American Health Organization (PAHO) ended its 172nd Session today, following discussions on a variety of pertinent public health topics, including pandemic response, vaccination coverage, strengthening human resources for health, strategic communications for behavior...

:: **[PAHO Executive Committee kicks off discussion on strategies and policies to improve the health of the people of the Americas](#)**

Washington, D.C., 26 June 2023 (PAHO/WHO)- The Executive Committee of the Pan American Health Organization (PAHO) began its 172nd session today. The Committee will examine the resolutions, strategies and policies to be presented to PAHO's 60th Directing Council in September, with the aim of improving the health of the population of the Americas....

**WHO South-East Asia Region** SEARO

*No new digest content identified.*

**WHO European Region** EURO

:: 30 June 2023 News release

**[WHO/Europe and the EPHA sign new MoU to strengthen collaboration for better health and well-being in Europe](#)**

:: 28 June 2023 Media release

**[New WHO–HBSC data shed light on COVID-19 pandemic's effects on children and adolescents](#)**

:: 27 June 2023 News release

**[Pandemic adversely affected the relationships and health of Hungarian adolescents, new data show](#)**

**WHO Western Pacific Region**

:: 28 June 2023

**[Working with the community to tailor health services to meet needs in Japan](#)**



.....

### **Disease Outbreak News (DONs)**

*Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.*

*No new digest content identified.*

.....

### **New WHO Publications**

<https://www.who.int/publications/i>

*Selected*

28 June 2023

**[Burden of disease attributable to unsafe drinking-water, sanitation and hygiene: 2019 update](#)**

28 June 2023

**[Use of bedaquiline in children and adolescents with multidrug- and rifampicin-resistant tuberculosis:...](#)**

28 June 2023

**[Use of delamanid in children and adolescents with multidrug- and rifampicin-resistant tuberculosis: information...](#)**

27 June 2023

**[Criteria for the certification of dracunculiasis eradication, 2023 update](#)**

26 June 2023

**[WHO's response to health emergencies: annual report 2022](#)**

.....

### **USA – HHS, FDA, CDC**

#### **HHS**

*News*

**[Statement from HHS Secretary Xavier Becerra on CDC's Historic Recommendation Allowing Older and Immunocompromised Adults to Receive the RSV Vaccine](#)**

June 29, 2023 News Release

*CDC Recommendation Follows the Advisory Committee on Immunization Practices' (ACIP)*

*Recommendations for the Use of New GSK and Pfizer RSV Vaccines for People Ages 60 Years and Older*

Today, in response to the Centers for Disease Control and Prevention's (CDC) recommendation of the Respiratory Syncytial Virus (RSV) vaccine for seniors over 60, U.S. Department of Health and Human Services (HHS) Secretary Xavier Becerra issued the following statement:

"For the first time in U.S. history, people 60 years and older can now receive a vaccine for protection against the RSV virus. With this CDC recommendation, the Administration is ensuring that Americans have access to stronger protection against circulating respiratory viruses. As we prepare for the fall

vaccine campaign, we will follow the data and science to protect our nation's most vulnerable older adults, those living in nursing or long-term care facilities, and the immunocompromised."

## **FDA**

*Press Announcements*

### **[June 29, 2023 - FDA Approves First Gene Therapy for Adults with Severe Hemophilia A](#)**

## **FDA VRBPAC**

*Advisory Committee Calendar*

*No new digest content identified.*

## **CDC/ACIP [U.S.] [to 01 Jul 2023]**

<http://www.cdc.gov/media/index.html>

*Latest News Releases*

### **[CDC Recommends RSV Vaccine For Older Adults](#)**

June 29, 2023

CDC Director Rochelle P. Walensky, M.D., M.P.H., endorsed the CDC Advisory Committee on Immunization Practices' (ACIP) recommendations for use of new Respiratory Syncytial Virus (RSV) vaccines from GSK and Pfizer for people ages 60 years and older, using shared clinical decision-making. This means these individuals may receive a single dose of the vaccine based on discussions with their healthcare provider about whether RSV vaccination is right for them.

Adults at the highest risk for severe RSV illness include older adults, adults with chronic heart or lung disease, adults with weakened immune systems, and adults living in nursing homes or long-term care facilities. CDC estimates that every year, RSV causes approximately 60,000–160,000 hospitalizations and 6,000–10,000 deaths among older adults.

These new vaccines – which are the first ones licensed in the U.S. to protect against RSV – are expected to be available this fall.

### **[Breakthrough Cures for Hepatitis C Still Fail to Reach the Vast Majority of Americans Who Need Them](#)**

June 29, 2023

A new CDC report suggests the majority of people with hepatitis C. still have not been cured nearly a decade after breakthrough treatments that clear the viral infection were first approved in the United States.

## **[ACIP Meetings](#)**

*Next ACIP Meeting: October 25-27*

## **MMWR Weekly**

<https://www.cdc.gov/mmwr/index2023.html>

### **June 23, 2023 / No. 245**

[PDF of this issue](#)

:: [Progress Toward Rubella Elimination — World Health Organization South-East Asia Region, 2013–2021](#)

:: [Trends in Laboratory-Confirmed SARS-CoV-2 Reinfections and Associated Hospitalizations and Deaths Among Adults Aged ≥18 Years — 18 U.S. Jurisdictions, September 2021–December 2022](#)

:: [Effectiveness of Up-to-Date COVID-19 Vaccination in Preventing SARS-CoV-2 Infection Among Nursing Home Residents — United States, November 20, 2022–January 8, 2023](#)

:: [Notes from the Field: Emergence of an Mpox Cluster Primarily Affecting Persons Previously Vaccinated Against Mpox — Chicago, Illinois, March 18–June 12, 2023](#)

.....  
.....

## Europe

### European Medicines Agency [EMA]

[https://www.ema.europa.eu/en/search/search/ema\\_editorial\\_content/ema\\_news?sort=field\\_ema\\_computed\\_date\\_field&order=desc](https://www.ema.europa.eu/en/search/search/ema_editorial_content/ema_news?sort=field_ema_computed_date_field&order=desc)

*News & Press Releases*

*No new digest content identified.*

.....

### European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports [Selected] News

[Epidemiological update: West Nile virus transmission season in Europe, 2022](#)

Epidemiological update - 30 Jun 2023

[ECDC and EASA formally retire joint Aviation Health Safety Protocol \(AHSP\)](#)

News - 29 Jun 2023

[Weekly COVID-19 country overview](#)

Epidemiological update - 29 Jun 2023

[Increasing risk of mosquito-borne diseases in EU/EEA following spread of Aedes species](#)

News - 22 Jun 2023

.....  
.....

### Africa CDC [to 01 Jul 2023]

<http://www.africacdc.org/>

*News*

[Statement by H.E Dr. Jean Kaseya, Director General of Africa CDC, on Gavi's announcement on Dr. Muhammad Pate's Decision to decline his Appointment as the next CEO for Gavi.](#)

27 June 2023

.....  
.....

### China CDC

<http://www.chinacdc.cn/en/>

**National Health Commission of the People's Republic of China** [to 01 Jul 2023]

<http://en.nhc.gov.cn/>

*News*

*No new digest content identified.*

**National Medical Products Administration – PRC** [to 01 Jul 2023]

<http://english.nmpa.gov.cn/>

*News*

**[Chinese drug regulators launch safety crackdown](#)**

2023-06-29

China's National Medical Products Administration has recently launched a nationwide drug safety consolidation and enhancement campaign to establish a solid foundation for drug safety.

**[China steps up efforts to prevent mpox spread](#)**

2023-06-29

China is redoubling its efforts to prevent the spread of the mpox disease, as a growing number of cases have been reported in certain parts of Asia and a few cases were found in Chinese cities including Beijing and Guangzhou, a health official said Tuesday.

**[China CDC Weekly Reports: Current Volume \(5\)](#)**

2023-06-30 / No. 26 **COVID-19 ISSUE (39)**

[View PDF of this issue](#)

- [Preplanned Studies: Persistent Urinary Tract Infection in Association with Community-Acquired NDM-5 Escherichia coli Clonal Group Following COVID-19 Infection — Beijing Municipality, China, 2023](#)
- [Preplanned Studies: Medical Consultations Option and Influencing Factors for SARS-CoV-2 Infected Individuals — Beijing Municipality, China, December 2022](#)
- [Recollection: Global Overview and Insights on Infodemiology and Infodemic Management](#)
- [Methods and Applications: Detecting SARS-CoV-2 BA.2, BA.4, and BA.5 Variants Utilizing a Robust RT-RPA-CRISPR/Cas12a-Based Method — China, 2023](#)

.....  
.....  
.....

**[Organization Announcements](#)**

**Paul G. Allen Frontiers Group** [to 01 Jul 2023]

<https://alleninstitute.org/news-press/>

*News*

*No new digest content identified.*

**BMGF - Gates Foundation** [to 01 Jul 2023]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

Press release Jun 28, 2023

**[Wellcome and the Gates Foundation to Fund Late-Stage Development of a Tuberculosis Vaccine Candidate That Could Be the First in 100 Years If Proven Effective](#)**

*TB is one of the world's deadliest diseases, killing about 4,300 people per day, mostly those living in poverty*

**Bill & Melinda Gates Medical Research Institute** [to 01 Jul 2023]

<https://www.gatesmri.org/news>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

*News: Articles and Publications*

*No new digest content identified.*

**CARB-X** [to 01 Jul 2023]

<https://carb-x.org/>

*News*

*No new digest content identified.*

**Center for Vaccine Ethics and Policy – GE2P2 Global Foundation** [to 01 Jul 2023]

<https://centerforvaccineethicsandpolicy.net/>

*News/Analysis/Publications-Digests/Statements*

:: **[Vaccines and Global Health: The Week in Review](#)** - Current edition

:: **[Informed Consent: A Monthly Review – June 2023](#)**

:: **[Genomic Medicine – Governance, Ethics, Policy, Practice: A Monthly Digest](#)** – June 2023

:: **[Public Consultations Watch :: Global Calls for Input/Public Comment/](#)** -

03 May 2023 – Issue 03

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 01 Jul 2023]

<http://cepi.net/>

*Latest News*

**[CEPI partners with RVAC Medicines to accelerate manufacturing of mRNA vaccines](#)**

*Funding of up to US\$3 million aims to accelerate the manufacturing process for RVAC's mRNA vaccine platform technology*

*News 27 Jun 2023*

**[SCARDA and CEPI collaborate to strengthen global pandemic preparedness and response](#)**

*Memorandum of Cooperation will enable sharing of expertise, knowledge and experience between the two organizations*

*News 26 Jun 2023*

*... On June 23, the [Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response \(SCARDA\)](#) of the [Japan Agency for Medical Research and Development](#)*

(AMED) and the Coalition for Epidemic Preparedness Innovations (CEPI) signed a Memorandum of Cooperation (MOC) to strengthen collaboration between the two organizations...

**CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 01 Jul 2023]

<https://cioms.ch/>

*News; Publications; Events*

### **Benefit-risk balance for medicinal products**

CIOMS Working Group VII report draft, 12 June 2023

Draft report: CIOMS WG XII For Comment 12June2023

Posted: 03 June 2023 Comments deadline: 24th of July 2023

The WG will build on previous considerations established by CIOMS WG IV, incorporating the latest thinking in quantitative and qualitative approaches to the evaluation of benefit-risk (B-R), as well as assimilating visual presentations of benefits and risks to improve transparency and understanding amongst key stakeholders, including patients. The perspective of healthcare professionals and patients will be considered based on other ongoing initiatives as well as new guidelines from regulatory authorities and public-private partnerships.

### **Real-World Data and Real-World Evidence in Regulatory Decision Making**

CIOMS Working Group XIII

Submissions deadline 14th of July 2023.

Draft: CIOMS WG XIII 6June2023 Draft report for comment

Background

There is increasing interest in the use of Real-World data (RWD) to support regulatory decision making across the product life cycle. Key sources of RWD are electronic health records, claims data, prescription data, and patient registries. Real-world evidence (RWE) is the clinical evidence about the usage and potential benefits or risks of a medical product derived from an analysis of RWD. For decades, such evidence has been well accepted for satisfying post-approval safety monitoring requirements but has not been used commonly to demonstrate drug effectiveness, which is a relatively new concept.

As applications are increasing, it is proposed that CIOMS develop a consensus report and recommendations for the use of RWD and RWE in regulatory decision-making related to biopharmaceutical products. This report will cover three key areas:

:: Articulate the different RWD/RWE requirements depending on the intent of use e.g. Regulatory, Payers, and Public Health;

:: Propose harmonized practices and guidance for using RWD and RWE for regulatory purposes (given that there are no existing consensus guidelines);

:: Articulate point of view (POV) on key ethical issues relevant to RWD and RWE and a provisional set of standards to address those issues (the high-level POV may lead to a separate/satellite group of ethicists to deal with it). Full Concept Note (31 March 2020)

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 01 Jul 2023]

<https://www.darpa.mil/news>

*News*

6/29/2023

### **DARPA Seeks to SHIELD Blood from Fungal and Bacterial Pathogens**

DARPA's new Synthetic Hemo-technologies that Locate & Disinfect (SHIELD) program aims to develop broad, preventive treatments for warfighters who suffer trauma from gunshot or blast wounds, or burns. Novel therapies would be administered as combat casualty care post-trauma with the aim to bind, clear, and defeat any fungi and bacteria in a pathogen-agnostic, or broad-spectrum manner before they can become a health risk. These therapies will be designed to protect the recipient for up to a week with a single dose; be durable, non-toxic, rapidly and broadly deployable; and be effective against the many different known and emerging bacterial and fungal threats.

**Duke Global Health Innovation Center** [to 01 Jul 2023]

<https://dukeghic.org/>

*Report*

*No new digest content identified.*

**EDCTP** [to 01 Jul 2023]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

30 June 2023

[EDCTP annual report 2022: Connecting numbers to impact](#)

**Emory Vaccine Center** [to 01 Jul 2023]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Vaccine Initiative** [to 01 Jul 2023]

<http://www.euvaccine.eu/>

*Latest News, Events*

*No new digest content identified.*

**Evidence Aid** [to 01 Jul 2023]

*Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.*

<http://www.evidenceaid.org/>

*Resources [Selected]*

*No new digest content identified.*

**Fondation Merieux** [to 01 Jul 2023]

<http://www.fondation-merieux.org/>

*News, Events*

June 26 – 28, 2023

*Mérieux Foundation co-organized event*

**[10th Annual Meeting of the Global Task Force on Cholera Control \(GTFCC\)](#)**

June 26 - 28, 2023

**Gavi** [to 01 Jul 2023]

<https://www.gavi.org/>

*News Releases*

28 June 2023

**[Global Vaccine Alliance to deploy six-in-one vaccine to lower-income countries, establish innovative mechanisms to protect against future epidemic threats](#)**

26 June 2023

**[David Marlow to Become Interim Chief Executive Officer of Gavi](#)**

**GHIT Fund** [to 01 Jul 2023]

<https://www.ghitfund.org/newsroom/press>

*Press Releases*

*No new digest content identified.*

**Global Fund** [to 01 Jul 2023]

<https://www.theglobalfund.org/en/news/>

*News & Stories*

*No new digest content identified.*

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 01 Jul 2023]

<https://www.glopid-r.org/news/>

*News*

**[Lessons learnt about setting research priorities in LMICs during health crises: New GloPID-R report highlights best practices for funders](#)**

June 27, 2023

**Hilleman Laboratories** [to 01 Jul 2023]

<http://www.hilleman-labs.org/>

*News & Insights*

*No new digest content identified.*

**HHMI - Howard Hughes Medical Institute** [to 01 Jul 2023]

<https://www.hhmi.org/news>

*Press Room*

*No new digest content identified.*



**Human Vaccines Project** [to 01 Jul 2023]

<http://www.humanvaccinesproject.org/>

News

*No new digest content identified.*

**IAVI** [to 01 Jul 2023]

<https://www.iavi.org/>

Latest News

Press Release June 30, 2023

**[IAVI launches multisite study with adolescent girls and young women to evaluate vaccine and antibody candidates for HIV prevention in sub-Saharan Africa](#)**

*First participants for the Multisite Adolescent Girls and Young Women study screened at the Centre for Family Health Research in Zambia.*

IAVI has announced the enrolment of the first 29 participants for the Multisite Adolescent Girls and Young Women (MAGY) study at the Centre for Family Health Research in Zambia (CFHRZ). Over the next three years, the MAGY study will collect and analyze a wide range of data from African adolescent girls and young women (AGYW) volunteers to inform the development of HIV prevention products.

Press Releases June 27, 2023

**[IAVI starts first-in-human Phase I clinical trial of single-dose Sudan virus vaccine candidate](#)**

NEW YORK – JUNE 27, 2023 – IAVI announced today that the first participants have been vaccinated with a Sudan virus (SUDV) vaccine candidate in a first-in-human Phase I clinical trial in the U.S. The IAVI-sponsored trial is funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).

Known as IAVI C108, this first-in-human study is designed to evaluate the safety and immunogenicity of an investigational SUDV vaccine candidate donated to IAVI by Merck (known as MSD outside the U.S. and Canada) to supplement IAVI's ongoing SUDV vaccine development program.

**IFA [International Federation on Aging]** [to 01 Jul 2023]

<https://ifa.ngo/>

News

**[16<sup>th</sup> Global Conference on Ageing](#)**

27th– 30th June 2023

Bangkok, Thailand

*[Numerous sessions involving vaccines/immunization and older populations]*

**INSERM** [to 01 Jul 2023]

<https://www.inserm.fr/en/home/>

Press Releases

*No new digest content identified.*

## **International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

## **ICH - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use** [to 01 Jul 2023]

<https://www.ich.org/page/press-releases>

*News/Pubs/Press Releases [Selective]*

27 June 2023

### **[Press Release: New collaboration between WHO International Classification of Diseases \(ICD\) and MedDRA launched](#)**

Today the World Health Organization (WHO) and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) are announcing a new collaboration to enhance registry and sharing of regulatory information on medical products worldwide.

20 June 2023

### **[Press Release: ICH Assembly Meeting, Vancouver, Canada, June 2023](#)**

The Assembly of the International Council for Harmonisation (ICH) met in-person on 12 & 13 June 2023, in Vancouver, Canada in parallel of meetings of 14 Working Groups, and preceded by meetings of the ICH Management Committee and the MedDRA Management Committee.

### **[Public Consultation: ICH E6\(R3\) Principles, Annex 1 and Annex 2](#)**

The E6(R3) EWG is working on the revision of the E6(R2) Guideline "Good Clinical Practice" (GCP) with a view to addressing the application of GCP principles to the increasingly diverse trial types and data sources being employed to support regulatory and healthcare related decision-making on drugs, and provide flexibility whenever appropriate to facilitate the use of technological innovations in clinical trials. Additional information may also be found in ICH Reflection Paper on "GCP Renovation" on the [ICH Reflection Paper page](#). When complete, E6(R3) will be composed of an overarching principles and objectives document, Annex 1 and Annex 2.

#### E6(R3) Draft Guideline

*Public consultation dates:*

ANVISA, Brazil - Deadline for comments by 31 August 2023

EC, Europe - Deadline for comments by 26 September 2023

MHRA, UK - Deadline for comments by 31 August 2023

TFDA, Chinese Taipei - Deadline for comments by 31 August 2023

## **[ICRC](#)** [to 015 Oct 2022]

<https://www.icrc.org/en/whats-new>

*What's New [Selected]*

### **[Annual Report 2022](#)**

The Annual Report 2022 is an account of the activities conducted by the ICRC over the past year.

29-06-2023 | Report

### **[ICRC list of suppliers and contractual information](#)**

ICRC has updated its procurement processes to align with transparency requirements for the use of large-scale public funding and to comply with EU regulations.  
26-06-2023 | Publication

**IFFIm**

<http://www.iffim.org/>

*Press Releases/Announcements*

*No new digest content identified.*

**IFRC** [to 01 Jul 2023]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Press Releases [Selected]*

**[Red Cross ramps up efforts as water-borne diseases threaten south of Ukraine](#)**

29/06/2023 | Press release

Kiev / Ukraine, 27 June 2023 – Water-borne diseases are a growing threat for people affected by flooding from the Nova Kakhovka Dam collapse earlier this month. This threat poses a significant challenge in an already complex and volatile situation. The International Federation of Red Cross and Red Crescent Societies (IFRC) network with the Ukrainian Red Cross Society continue to scale up to help tackle the new risk...

**Institut Pasteur** [to 01 Jul 2023]

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*No new digest content identified.*

**ISC / International Science Council** [to 01 Jul 2023]

<https://council.science/current/>

*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

*No new digest content identified.*

**International Union of Immunological Societies (IUIS)**

<https://iuis.org/>

*News/Events [Selected]*

**[WCP2023 – 19th World Congress of Basic and Clinical Pharmacology](#)**

Sunday 2nd July 2023

In 2023, the global pharmacology and therapeutics community will unite in Glasgow, Scotland, Sunday 2nd July 2023.

**IVAC** [to 01 Jul 2023]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

*No new digest content identified.*

**IVI** [to 01 Jul 2023]

<http://www.ivi.int/>

*IVI News & Announcements*

**[IVI welcomes three new members to its Board of Trustees](#)**

06/27/2023

IVI's Board of Trustees is delighted to welcome three new members: Dr. Nakorn Prem Sri, who began his 3-year term in May, and Yanchun Lily Li and Richard C. Henriques who will begin their service at the next Board meeting in November 2023. Together, they bring deep expertise in vaccine research and development, public health, international business, and finance, along with invaluable experience working with and within government, pharmaceutical companies, and philanthropies...

**Johns Hopkins Center for Health Security** [to 01 Jul 2023]

<https://www.centerforhealthsecurity.org/news/center-news/>

*Center News [Selected]*

*No new digest content identified.*

**MSF/Médecins Sans Frontières** [to 01 Jul 2023]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Medical resource*

**[MSF's latest medical guidelines provide practical recommendations for health pro...](#)**

30 Jun 2023

- Médecins Sans Frontières (MSF) has published the latest edition of our its main medical guidelines 'Clinical guidelines' and 'Essential drugs'.
- Both guidelines are available in Arabic, English, French and Spanish for use in MSF projects and beyond.
- They are available in both printed and digital versions, with the digital version accessible via both the [MSF medical guidelines website](#) and a mobile application.

*Somalia*

**[Recovering from multidrug-resistant tuberculosis in Somaliland](#)**

28 Jun 2023

**National Academy of Medicine - USA** [to 01 Jul 2023]

<https://nam.edu/programs/>

*News [Selected]*

**[NAM Member Named to Head CDC](#)**

June 29, 2023

President Biden announced his intent to appoint National Academy of Medicine member Mandy Cohen to serve as director of the Centers for Disease Control and Prevention. A physician and public [...]

**[NAM Shares Resources in Support of Assessing Meaningful Community Engagement to Advance Health Equity](#)**

June 21, 2023

A suite of implementation-focused resources follows the release of an innovative Conceptual Model from the Assessing Meaningful Community Engagement in Health & Health Care Programs & Policies project. Meaningful community [...]

**[NAM Leadership Consortium Collaborates with Leading Health, Tech, Research, and Bioethics Organizations to Develop Health Care AI Code of Conduct](#)**

June 20, 2023

The NAM launches a 3-year project convening health, tech, research, and bioethics leaders in producing a code of conduct for the development and use of Artificial Intelligence in health, medical [...]

**National Academy of Sciences** - USA [to 01 Jul 2023]

<https://www.nationalacademies.org/newsroom?>

*News*

**[National Academies Presidents' Statement on Affirmative Action](#)**

Statement | June 30, 2023

**National Vaccine Program Office** - U.S. HHS [to 01 Jul 2023]

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

**[September 21-22, 2023 NVAC Meeting](#)**

**NIH** [to 01 Jul 2023]

<http://www.nih.gov/>

*News Releases*

*No new digest content identified.*

**PATH** [to 01 Jul 2023]

<https://www.path.org/media-center/>

*Press Releases*

*No new digest content identified.*

**Rockefeller Foundation** [to 01 Jul 2023]

<https://www.rockefellerfoundation.org/>

*Selected Reports/Press Releases*

*No new digest content identified.*

**Sabin Vaccine Institute** [to 01 Jul 2023]

<https://www.sabin.org/press/>  
*Latest News & Press Releases*  
*No new digest content identified.*

**UNAIDS** [to 01 Jul 2023]  
<http://www.unaids.org/en>  
*Selected Press Releases/Reports/Statements*

29 June 2023  
[Supporting women and girls affected by gang violence in Haiti](#)

27 June 2023  
[Highlighting the role that faith communities are playing to end AIDS in children and adolescents](#)

26 June 2023  
[The Denver Principles: 40 years on](#)

**UNICEF** [to 01 Jul 2023]  
<https://www.unicef.org/media/press-releases>  
*Latest press releases, news notes and statements*  
*Press release 26 June 2023*  
[More than 100,000 children fleeing Sudan conflict face new dangers amid desperate situation in Chad](#)  
<https://www.unicef.org/press-releases/more-100000-children-fleeing-sudan-conflict-face-new-dangers-amid-desperate>  
NEW YORK/DAKAR/N'DJAMENA, 26 June 2023– Children and families who have arrived in Eastern Chad in search of safety after fleeing the intensifying conflict in the neighbouring Sudanese region of Darfur, now face

**Unitaid** [to 01 Jul 2023]  
<https://unitaid.org/>  
*Featured News*  
*No new digest content identified.*

**Vaccine Equity Cooperative [nee Initiative]** [to 01 Jul 2023]  
<https://vaccineequitycooperative.org/news/>  
*News*  
Jun 30, 2023  
[Media: COVID-19 Communication Campaigns for Vaccination: An Assessment with Perspectives for Future Equity-Centered Public Health Efforts](#)  
With a focus on racial health equity, the Vaccine Equity Cooperative (VEC) spearheaded a high-level landscape analysis of COVID-related communication campaigns.

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 01 Jul 2023]

<https://www.vaccineacceptance.org/>

*Announcements, Blog*

*No new digest content identified.*

**Vaccine Confidence Project** [to 01 Jul 2023]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

*No new digest content identified.*

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 01 Jul 2023]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

**[Vaccine Update Newsletter June 2023](#)**

Vaccine Update is our monthly email newsletter that will keep you up to date on current vaccine-related issues.

**Wellcome Trust** [to 01 Jul 2023]

<https://wellcome.ac.uk/news>

*News, Opinion, Reports*

*News*

**[The world’s first tuberculosis vaccine in 100 years could be in sight](#)**

27 June 2023 6-minute read

The world needs a new vaccine to fight tuberculosis (TB). A new multimillion-pound global study funded by Wellcome and the Bill & Melinda Gates Foundation could provide a solution.

**The Wistar Institute** [to 01 Jul 2023]

<https://www.wistar.org/news/press-releases>

*Press Releases*

*No new digest content identified.*

**WFPHA: World Federation of Public Health Associations** [to 01 Jul 2023]

<https://www.wfpha.org/>

*Latest News - Blog*

**[IC2PerMed: Roadmap](#)**

Jun 30, 2023

IC2PerMed: Roadmap Integrating China in the International Consortium for Personalized Medicine (IC2PerMed) project aims to support the European Union (EU)-China collaboration over the developments of personalized medicine research, innovations, and...

**[World Medical Association \[WMA\]](#)** [to 01 Jul 2023]

<https://www.wma.net/news-press/press-releases/>  
*Press Releases*  
*No new digest content identified.*

**World Organisation for Animal Health (OIE)** [to 01 Jul 2023]

<https://www.oie.int/en/>  
*Press Releases, Statements*  
*Joint Press Release*

**[OFFLU's annual report: tackling animal influenza through data sharing](#)**

Published on 27 June 2023

*In a world facing increasing global health challenges, collaboration and data sharing have emerged as powerful tools for combating infectious diseases. As a vital network of experts focused on animal influenza, OFFLU showcases in a recent report their commitment to collaboration and information exchange.*

The 2022 annual report of the WOAH/FAO Network of Expertise on Animal Influenza (OFFLU) highlights its significant contributions in sharing critical scientific data, advancing pandemic preparedness vaccines, and promoting diagnostic capabilities worldwide. Through collaborative efforts with international organizations, OFFLU strives to enhance global health and preparedness in combating avian, swine, and equine influenza, while safeguarding animal and human populations against the risks posed by these infectious diseases. ..

.....

**ARM [Alliance for Regenerative Medicine]** [to 01 Jul 2023]

<https://alliancerm.org/press-releases/>  
*Selected Press Releases*  
*No new digest content identified.*

**BIO** [to 01 Jul 2023]

<https://www.bio.org/press-releases>  
*Press Releases*

**[New CMS guidance a "missed opportunity" for future medical innovation, patients](#)**

June 30, 2023

The Centers for Medicare & Medicaid Services (CMS) today released its guidance for the Drug Price Negotiation Program (Negotiation Program) under the Inflation Reduction Act of 2022 (IRA).

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 01 Jul 2023]

<http://www.dcvmn.org/>  
*News; Upcoming events*  
*No new digest content identified.*

**ICBA – International Council of Biotechnology Associations** [to 01 Jul 2023]

<https://internationalbiotech.org/news/>  
*News*



*No new digest content identified.*

**IFPMA** [to 01 Jul 2023]

<https://ifpma.org/>

*Selected Press Releases/Statement*

*Expert insight*

**[How the COVID-19 pandemic sparked innovation in clinical trials: considerations for the future](#)**

29 June 2023

Sarah Adam Associate Director, Regulatory Affairs

The approval of a safe and effective vaccine for COVID-19, only less than a year after the SARS-CoV-2 outbreak, is a scientific marvel. Vaccine development is in fact usually a slow and resource-intensive process that can take over ten years.

**International Alliance of Patients' Organizations – IAPO** [to 01 Jul 2023]

<https://www.iapo.org.uk/news/topic/6>

*Press and media [Selected]*

*No new digest announcements identified*

**International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

**[IGBA Welcomes ICH New Topic for Harmonisation: "Bioequivalence for Modified-Release Products" \(June 2023\)](#)**

26 June 2023

The International Generic and Biosimilar Medicines Association (IGBA) commends the General Assembly of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) for its adoption of a new topic focused on the harmonisation of "Bioequivalence for Modified-Release Products." This significant development, which took place at the recent ICH meeting in Vancouver, Canada, marks the introduction of a new ICH Multidisciplinary Guideline, which aims to further strengthen consensus and harmonisation among ICH members regarding bioequivalence standards for more complex dosage forms. These efforts build upon the existing harmonisation initiatives found within the upcoming M13 series of bioequivalence guidelines.

**PhRMA** [to 01 Jul 2023]

<http://www.phrma.org/>

*Press Releases*

*No new digest announcements identified*

.....

.....

**Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements**

## **AstraZeneca**

*Press Releases*

[\*\*AstraZeneca announces \\$400 million investment in reforestation and biodiversity in support of climate action and human health\*\*](#)

28 June 2023

## **Bharat Biotech**

*Press Releases* - No new digest announcements identified

**BioCubaFarma** – Cuba

*Últimas Noticias* - Website not responding at inquiry

## **Biological E**

*News* No new digest announcements identified

## **BioNTech**

*Press Releases*

29 June 2023

[\*\*BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC\*\*](#)

- Initiation of pivotal Phase 3 trial in non-small cell lung cancer (NSCLC) marks the first landmark in BioNTech's and OncoC4's strategic collaboration initiated in March 2023 with the aim to evaluate BNT316/ONC-392 in various solid tumor indications
- The randomized Phase 3 trial is expected to enroll approximately 600 patients with metastatic, immunotherapy-resistant NSCLC at clinical trial sites initially in the United States, followed by Europe and other countries and regions
- The trial initiation follows the FDA Fast Track Designation granted in 2022, based on Phase 1/2 safety and efficacy data for the monotherapy in metastatic, immunotherapy-resistant NSCLC
- BNT316/ONC-392 is entering the pivotal clinical evaluation as part of BioNTech's strategy to initiate multiple trials with registrational potential in 2023 and 2024

## **Boehringer**

*Press Releases* - No new digest announcements identified

## **CanSinoBIO**

*News* - Website not responding at inquiry

## **CIGB**

*Latest News*

[\*\*IV International Symposium Cancer 2023\*\*](#)

Varadero, Cuba, September, 2023

## **Cinnagen**

*Recent News* - No new digest announcements identified

**Clover Biopharmaceuticals** - China

*News* - No new digest announcements identified

## **Curevac [Bayer Ag – Germany]**

[News](#) - No new digest announcements identified

## **Gamaleya National Center**

[Latest News and Events](#) - See Russia above.

## **GSK**

[Press releases for media](#)

27 June 2023

### **[GSK receives US FDA Fast Track designation for investigational vaccine against gonorrhoea](#)**

Fast Track designation accelerates the vaccine candidate's path to US FDA submission for the prevention of Neisseria gonorrhoeae infection

26 June 2023

### **[Japan's Ministry of Health, Labour and Welfare approves Shingrix for the prevention of shingles in at-risk adults aged 18 and over](#)**

Approval expands the number of people who can be protected against shingles.

## **IMBCAMS, China**

[Home](#) - Website not responding at inquiry

## **Janssen/JNJ**

[Press Releases](#) - No new digest announcements identified

## **Merck**

[News releases](#) - No new digest announcements identified

## **Moderna**

[Press Releases](#) - No new digest announcements identified

## **Nanogen**

[News](#) - No new digest announcements identified

## **Novartis**

[News](#) - No new digest announcements identified

## **Novavax**

[Press Releases](#) - No new digest announcements identified

## **Pfizer**

[Recent Press Releases](#) - No new digest announcements identified

## **R-Pharm**

<https://rpharm-us.com/index.php>

[No news or media page identified]

## **Sanofi Pasteur**

[Press Releases](#)

June 29, 2023

**[Press Release: Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease](#)**

- Sanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030, fueled by an accelerated pace of innovation
- Intent to start at least 5 innovative Phase 3 vaccine programs by 2025

**Serum Institute of India**

[NEWS & ANNOUNCEMENTS](#) - No new digest announcements identified

**Sinopharm/WIBPBIBP**

[News](#) - No new digest announcements identified

**Sinovac**

[Press Releases](#) - No new digest announcements identified

2023/06/30 | [Press Releases](#)

**[SINOVAC's Healive® Maintains Three-Decade-Long Immunity in 15-Year Study](#)**

June 30, 2023, Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced promising findings from a 15-year study on the efficacy of its hepatitis A vaccine, Healive®. The findings confirm Healive® maintains a seroconversion rate of 97.9% at 15 years post-vaccination, as well as predicts long-lasting immunity exceeding three decades, providing robust evidence-based support for the administration of hepatitis A vaccines and continued development of immunization strategies.

Healive® is the first and only hepatitis A vaccine from China prequalified by the World Health Organization. To date, over 100 million doses have been administered in more than 30 countries and regions...

**SK Biosciences**

[Press Releases](#)

**[SK bioscience-Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate](#)**

-The 21-valent pneumococcal conjugate vaccine candidate, GBP410 (also known as SP0202), demonstrates...

2023.06.30

**[SK bioscience and the Peter Doherty Institute for Infection and Immunity Join Forces Against Influenza](#)**

SK bioscience will collaborate with one of the world's leading biomedical research institutes, the P...

2023.06.27

**Takeda**

[Newsroom](#) - No new digest announcements identified

**Valneva**

[Press Releases](#) - No new digest announcements identified

**Vector State Research Centre of Virology and Biotechnology**

[Home](#) - Website not responding [404 error]

## **WestVac Biopharma**

*Media - No new digest announcements identified*

## **Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]



### ***Contents [click to move among sections]***

:: [Coronavirus \[COVID-19\]](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)



### ***Journal Watch***

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

## **AJOB Empirical Bioethics**

Volume 14, 2023 Issue 2

<https://www.tandfonline.com/toc/uabr21/current>

*Article*

[Reviewed earlier]

## **AMA Journal of Ethics**

Volume 25, Number 6: E381-465 June 2023

<https://journalofethics.ama-assn.org/issue/ipe-and-innovation>

### ***Patient-Centered Transgender Surgical Care***

The November 2016 issue of the journal, *Transgender Health*, focused on the importance of expanding gender-affirming health care services, enhancing the quality of transgender patients' clinical encounters, and improving general medical and mental health outcomes among gender diverse patients. This current issue follows up on that initial inquiry, delving specifically into relationships among autonomy protections and patient-centered informed consent and shared decision-making processes in gender-affirming surgical care.

**American Journal of Infection Control**

June 2023 Volume 51 Issue 6 p603-724

<http://www.ajicjournal.org/current>

[Reviewed earlier]

**American Journal of Preventive Medicine**

June 2023 Volume 64 Issue 6 p781-940

<http://www.ajicjournal.org/current>

[Reviewed earlier]

**American Journal of Public Health**

July 2023 113(7)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

**American Journal of Tropical Medicine and Hygiene**

Volume 108 (2023): Issue 6 (Jun 2023)

<https://www.ajtmh.org/view/journals/tpmd/108/5/tpmd.108.issue-6.xml>

[Reviewed earlier]

**Annals of Internal Medicine**

June 2023 Volume 176, Issue

<https://www.acpjournals.org/toc/aim/current>

*Original Research*

**[Distributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease in the United States](#)**

George Goshua, MD, MSc, Cecelia Calhoun, MD, MBA, MPH, Satoko Ito, MD, PhD, [... et al.](#)

Pages:779–787

Gene therapy is a potential cure for sickle cell disease (SCD). Conventional cost-effectiveness analysis (CEA) does not capture the effects of treatment on disparities in SCD. This study compared gene therapy versus standard of care in patients with SCD by using conventional CEA and distributional CEA.

*Reviews*

**[Major Update: Masks for Prevention of SARS-CoV-2 in Health Care and Community Settings—Final Update of a Living, Rapid Review](#)**

FREE

Roger Chou, MD, and Tracy Dana, MLS

Pages:827–835

This systematic review is the final update of a living systematic review on the use of masks for prevention of SARS-CoV-2 in health care and community settings. The authors summarize changes from the last update and the cumulation of evidence from randomized trials and observational studies on use of masks for the prevention of COVID-19.

### **Artificial Intelligence – An International Journal**

Volume 319 June 2023

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/319/suppl/C>

[Reviewed earlier]

### **BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 01 Jul 2023)

[No new digest content identified]

### **BMJ Global Health**

June 2023 - Volume 8 - 6

<https://gh.bmj.com/content/8/6>

[Reviewed earlier]

### **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 01 Jul 2023)

[No new digest content identified]

### **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 01 Jul 2023)

[No new digest content identified]

### **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 01 Jul 2023)

[No new digest content identified]

### **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 01 Jul 2023)

[No new digest content identified]

### **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 01 Jul 2023)

[No new digest content identified]

## **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 01 Jul 2023)

### **[Vaccine coverage and effectiveness against laboratory-confirmed symptomatic and severe Covid-19 in indigenous people in Brazil: a cohort study](#)**

*Indigenous people have historically suffered devastating impacts from epidemics and continue to have lower access to healthcare and be especially vulnerable to respiratory infections. We estimated the coverage...*

Authors: Julia M. Pescarini, Andrey M. Cardoso, Ricardo Ventura Santos, Priscila F. Scaff, Enny S. Paixao, Otavio T. Ranzani, Thiago Cerqueira-Silva, Viviane S. Boaventura, Juracy Bertoldo-Junior, Vinicius A. de Oliveira, Guilherme L. Werneck, Mauricio L. Barreto and Manoel Barral-Netto

Citation: BMC Public Health 2023 23:1267

Content type: Research Published on: 29 June 2023

### **[A systematic review of interventions to promote HPV vaccination globally](#)**

*Despite the human papillomavirus (HPV) vaccine being a safe, effective cancer prevention method, its uptake is suboptimal in the United States (U.S.). Previous research has found a variety of intervention stra...*

Authors: Cam Escoffery, Courtney Petagna, Christine Agnone, Stephen Perez, Lindsay B. Saber, Grace Ryan, Meena Dhir, Swathi Sekar, Katherine A. Yeager, Caitlin B. Biddell, Purnima Madhivanan, Stephanie Lee, Amanda S. English, Lara Savas, Eliza Daly, Thuy Vu...

Citation: BMC Public Health 2023 23:1262

Content type: Research Published on: 29 June 2023

### **[Vaccination in the childhood and awareness of basic public health services program among internal migrants: a nationwide cross-sectional study](#)**

*Vaccination is proved to be one of the most effective and efficient way to prevent illness and reduce health inequality. Studies about association between vaccination inequalities in the childhood and awarenes...*

Authors: Jun Wang, Yang Bai, Jingmin Zhu, Xueyao Wang and Jue Liu

Citation: BMC Public Health 2023 23:1257

Content type: Research Published on: 28 June 2023

### **[Acceptance of COVID-19 vaccination among parents of children with autism and other neurodevelopmental disorders in Saudi Arabia: a cross-sectional study](#)**

*Acceptance of COVID-19 vaccination was noticed to be less common among parents of children with autism spectrum disorder (ASD) and other neurodevelopmental disorders. This study aimed to explore the beliefs an...*

Authors: Ali Jawad Al Saad, Ghadeer Mohammed Alhassan, Maryam Saleh Albedaiwi, Fatimah Fathi Alqattan, Fatimah Ali Alessa and Hawra Wasel Alabdulmohsen

Citation: BMC Public Health 2023 23:1235

Content type: Research Published on: 26 June 2023

## **BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>



(Accessed 01 Jul 2023)  
[No new digest content identified]

**BMJ Evidence-Based Medicine**

June 2023 - Volume 28 - 3  
<https://ebm.bmj.com/content/28/3>  
[Reviewed earlier]

**BMJ Open**

May 2023 - Volume 13 - 5  
<https://bmjopen.bmj.com/content/13/1>  
[Reviewed earlier]

**Bulletin of the Atomic Scientists**

May 2023  
<https://thebulletin.org/magazine/2023-05/>  
[Reviewed earlier]

**Bulletin of the World Health Organization**

Volume 101(6); 2023 Jun 1  
<https://www.ncbi.nlm.nih.gov/pmc/issues/436846/>  
[Reviewed earlier]

**Cell**

Jun 22, 2023 Volume 186 Issue 13 p2719-2950  
<https://www.cell.com/cell/current>  
{New issue; No digest content identified]

**Child Care, Health and Development**

Volume 49, Issue 3 Pages: 407-616 May 2023  
<https://onlinelibrary.wiley.com/toc/13652214/current>  
[Reviewed earlier]

**Clinical Pharmacology & Therapeutics**

Volume 113, Issue 6 Pages: 1163-1378 June 2023  
<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>  
[Reviewed earlier]

**Clinical Therapeutics**

May 2023 Volume 45 Issue 5 p387-482

<http://www.clinicaltherapeutics.com/current>  
[Reviewed earlier]

### **Clinical Trials**

Volume 20 Issue 3, June 2023  
<https://journals.sagepub.com/toc/ctja/20/3>  
*Articles*  
[Reviewed earlier]

### **Conflict and Health**

<http://www.conflictandhealth.com/>  
[Accessed 01 Jul 2023]  
[No new digest content identified]

### **Contemporary Clinical Trials**

Volume 129 June 2023  
<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/129/suppl/C>  
*Research article Full text access*

#### **[The effect of the COVID-19 pandemic on US Food and Drug Administration-funded clinical trials and natural history studies for rare diseases](#)**

Kathleen L. Miller, Katherine I. Miller Needleman  
Article 107198

*Research article Full text access*

#### **[The impact of COVID-19 on a large pragmatic clinical trial embedded in primary care](#)**

Sarah M. Leatherman, Cynthia Hau, Alison Klint, Peter A. Glassman, ... Areef Ishani  
Article 107179

### **The CRISPR Journal**

Volume 6, Issue 3 / June 2023  
<https://www.liebertpub.com/toc/crispr/6/3>  
[Reviewed earlier]

### **Current Genetic Medicine Reports**

Volume 10, issue 3, September 2022  
<https://link.springer.com/journal/40142/volumes-and-issues/10-3>  
[Reviewed earlier]

### **Current Medical Research and Opinion**

Volume 39, Issue 6 2023  
<https://www.tandfonline.com/toc/icmo20/current>  
[Reviewed earlier]

### **Current Opinion in Infectious Diseases**

June 2023 - Volume 36 - Issue 3

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

### **Current Protocols in Human Genetics**

Volume 108, Issue 1 December 2020

<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>

[Reviewed earlier]

### **Developing World Bioethics**

Volume 23, Issue 2 Pages: 89-195 June 2023

<https://onlinelibrary.wiley.com/toc/14718847/current>

***Special Issue: Reproductive Justice: Inequalities in the Global South***

[Reviewed earlier]

### **Development in Practice**

Volume 33, Issue 4, 2023

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

### **Development Policy Review**

Volume 41, Issue 3 May 2023

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

### **Disaster Medicine and Public Health Preparedness**

Volume 16 - Issue 6 - December 2022

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

### **Disasters**

Volume 47, Issue 2 Pages: 245-542 April 2023

<https://onlinelibrary.wiley.com/toc/14677717/2023/47/2>

[Reviewed earlier]

### **EMBO Reports**

Volume 24 Issue 65 June 2023

<https://www.embopress.org/toc/14693178/current>  
[Reviewed earlier]

### **Emerging Infectious Diseases**

Volume 29, Number 6—June 2023

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

### **Epidemics**

Volume 43 June 2023

<https://www.sciencedirect.com/journal/epidemics/vol/43/suppl/C>

[Reviewed earlier]

### **Epidemiology and Infection**

Volume 151 - 2023

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

### **Ethics & Human Research**

Volume 45, Issue 3 Pages: 1-44 May–June 2023

<https://onlinelibrary.wiley.com/toc/25782363/current>

**:: Advance research directives :: Translational research ethics**

[Reviewed earlier]

### **Ethics & International Affairs**

Volume 37 - Issue 1 - Spring 2023

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

### **Ethics, Medicine and Public Health**

Volume 28 June 2023

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/28/suppl/C>

[Reviewed earlier]

### **The European Journal of Public Health**

Volume 33, Issue 3, June 2023

<https://academic.oup.com/eurpub/issue/33/3>

[Reviewed earlier]

### **Expert Review of Vaccines**

Vol 22 (1) 2023 *Issue In Progress*  
<https://www.tandfonline.com/toc/ierv20/current>  
[Reviewed earlier]

### **Foreign Affairs**

May/June 2023 Volume 102, Number 3  
<https://www.foreignaffairs.com/issues/2023/102/3>  
[Reviewed earlier]

### **Forum for Development Studies**

Volume 50, 2023 - Issue 2  
<http://www.tandfonline.com/toc/sfds20/current>  
[Reviewed earlier]

### **Genetics in Medicines**

Volume 25, Issue 6 June 2023  
<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/25/issue/6>  
[Reviewed earlier]

### **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>  
[Accessed 01 Jul 2023]  
[No new digest content identified]

### **Global Health Action**

Volume 16, Issue 1 (2023)  
<https://www.tandfonline.com/toc/zgha20/current?nav=toCList>  
[Reviewed earlier]

### **Global Health: Science and Practice (GHSP)**

Vol. 11, No. 3 June 21, 2023  
<http://www.ghspjournal.org/content/current>  
[Reviewed earlier]

### **Global Legal Monitor – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>  
[Accessed 01 Jul 2023]  
[No new digest content identified]

### **Global Public Health**

Volume 18, Issue 1 (2023)  
<http://www.tandfonline.com/toc/rgph20/current>  
[Reviewed earlier]

### **Globalization and Health**

<http://www.globalizationandhealth.com/>  
[Accessed 01 Jul 2023]  
[No new digest content identified]

### **Health and Human Rights**

Volume 25, Issue 1, June 2023,  
<https://www.hhrjournal.org/special-section-global-voices-for-global-equity-expanding-right-to-health-frameworks/>

#### ***Special Section: Global Voices for Global Justice: Expanding Right to Health Frameworks***

...The papers in this special section work together to move toward a global social medicine for the 22nd century. They envision a global social medicine that confronts and moves beyond the traditionally colonial, xenophobic, heteronormative, patriarchal, gender-binary-bound, capitalist, and racist histories of the fields of global health and human rights. They seek to instantiate a global social medicine that centers knowledge and experiences from the Global South and works toward social justice and health equity at scale. In this special section, the authors are particularly interested in understanding, challenging, and expanding our perspectives and enactments of the right to health. Unlike neoliberal perspectives on health that often limit their explanatory capacity to how individuals behave in the world, the papers here move beyond the focus on lifestyles and on the phantasmagoria of a sovereign subject with supposedly free agency. Instead, authors work toward critical consciousness that accounts for structural processes—with their inequities and disruptions, as well as their effects on individuals—and how this consciousness can open new horizons for collective transformation and social emancipation in health...

### **Health Economics, Policy and Law**

Volume 18 - Issue 3 - July 2023  
<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>  
[Reviewed earlier]

### **Health Policy and Planning**

Volume 38, Issue 5, June 2023  
<https://academic.oup.com/heapol/issue/38/5>  
[Reviewed earlier]

### **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>  
[Accessed 01 Jul 2023]  
[No new digest content identified]

### **Human Gene Therapy**

Volume 34, Issue 11-12 / June 2023

<https://www.liebertpub.com/toc/hum/34/11-12>

#### ***Special Issue on Inflammation Networks in Gene Therapy***

[Reviewed earlier]

### **Humanitarian Practice Network**

<https://odihpn.org/>

*Featured Publications*

[No new digest content identified]

### **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 18, Issue 5, 2022

<https://www.tandfonline.com/toc/khvi20/18/5?nav=tocList>

[Reviewed earlier]

### **Immunity**

June 13, 2023 Volume 56 Issue 6 p1153-1428

<https://www.cell.com/immunity/current>

[Reviewed earlier]

### **Infectious Agents and Cancer**

<http://www.infectagentscancer.com/>

[Accessed 01 Jul 2023]

[No new digest content identified]

### **Infectious Diseases of Poverty**

<http://www.idpjournals.com/content>

[Accessed 01 Jul 2023]

[No new digest content identified]

### **International Health**

Volume 15, Issue 3, May 2023

<https://academic.oup.com/inthealth/issue/15/3>

[Reviewed earlier]

### **International Human Rights Law Review**

Volume 11 (2022): Issue 2 (Dec 2022)

<https://brill.com/view/journals/hrlr/11/2/hrlr.11.issue-2.xml>

*Table of Contents*

[Reviewed earlier]

**International Journal of Community Medicine and Public Health**

Vol. 10 No. 5 (2023): May 2023

<https://www.ijcmph.com/index.php/ijcmph/issue/view/100>

[Reviewed earlier]

**International Journal of Epidemiology**

Volume 52, Issue 3, June 2023

<https://academic.oup.com/ije/issue>

[New issue; No digest content identified]

**International Journal of Human Rights in Healthcare**

Volume 16 Issue 1 2023

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/16/iss/1>

[Reviewed earlier]

**JAMA**

June 27, 2023, Vol 329, No. 24, Pages 2109-2202

<https://jamanetwork.com/journals/jama/currentissue>

[New issue; No digest content identified]

**JAMA Health Forum**

June 2023, Vol 4, No. 6

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

**JAMA Pediatrics**

June 2023, Vol 177, No. 6, Pages 551-651

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

**JBI Evidence Synthesis**

June 2023 - Volume 21 - Issue 6

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

**Journal of Adolescent Health**

July 2023 Volume 73 Issue 1 p1-212

<https://www.jahonline.org/current>



[Reviewed earlier]

### **Journal of Artificial Intelligence Research**

Vol. 77 (2023)

<https://www.jair.org/index.php/jair>

*Contents*

[Reviewed earlier]

### **Journal of Community Health**

Volume 48, issue 3, June 2023

<https://link.springer.com/journal/10900/volumes-and-issues/48-3>

[Reviewed earlier]

### **Journal of Current Medical Research and Opinion**

*...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.*

June 18, 2023 Vol 6, No 06 (2023)

<https://www.cmro.in/index.php/jcmro/issue/view/68>

[New issue; No digest content identified]

### **Journal of Development Economics**

Volume 163 June 2023

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/163/suppl/C>

*Research article Open access*

[\*\*The macroeconomics of pandemics around the world: Lives versus livelihoods revisited\*\*](#)

Ingvild Almås, Tessa Bold, Tillmann von Carnap, Selene Ghisolfi, Justin Sandefur

Article 103099

### **Journal of Empirical Research on Human Research Ethics**

Volume 18 Issue 3, July 2023

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

### **Journal of Epidemiology & Community Health**

June 2023 - Volume 77 - 6

<https://jech.bmj.com/content/77/4>

[New issue; No digest content identified]

### **Journal of Evidence-Based Medicine**

Volume 16, Issue 1 Pages: 1-100 March 2023

<https://onlinelibrary.wiley.com/toc/17565391/current>  
[Reviewed earlier]

**Journal of Global Ethics**

Volume 19, Issue 1 (2023)

<http://www.tandfonline.com/toc/rjge20/current>  
[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 34, Number 2, May 2023

<https://muse.jhu.edu/issue/50186>

*Table of Contents*

[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 25, issue 3, June 2023

<https://link.springer.com/journal/10903/volumes-and-issues/25-3>

*Contents*

[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 21, 2023 \_ Issue 2

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

**Journal of Infectious Diseases**

Volume 227, Issue 7, 1 April 2023

<https://academic.oup.com/jid/issue/227/7>

[Reviewed earlier]

**Journal of International Development**

Volume 35, Issue 4 Pages: 537-668 May 2023

<https://onlinelibrary.wiley.com/toc/10991328/current>

***Special Issue: China and India in Africa***

[Reviewed earlier]

**Journal of Medical Ethics**

June 2023 - Volume 49 - 6

<http://jme.bmj.com/content/current>

[Reviewed earlier]

**Journal of Patient-Centered Research and Reviews**

Volume 10, Issue 1 (2023)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

**Journal of Pediatrics**

June 2023 Volume 257

<http://www.jpeds.com/current>

*Reflections on Ethics and Advocacy in Child Health*

[Reviewed earlier]

**Journal of Pharmaceutical Policy and Practice**

<https://joppp.biomedcentral.com/>

[Accessed 01 Jul 2023]

[No new digest content identified]

**Journal of Public Health Management & Practice**

May/June 2023 - Volume 29 - Issue 3

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

**Journal of Public Health Policy**

Volume 44, issue 2, June 2023

<https://link.springer.com/journal/41271/volumes-and-issues/44-2>

*Articles*

[Reviewed earlier]

**Journal of the Royal Society – Interface**

June 2023 Volume 20 Issue 203

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

**Journal of Travel Medicine**

Volume 30, Issue 4, May 2023

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

**Journal of Virology**

Volume 97 Number 4 April 2023

<http://jvi.asm.org/content/current>

[Reviewed earlier]

### **The Lancet**

Jul 01, 2023 Volume 402 Number 10395 p1-78

<https://www.thelancet.com/journals/lancet/issue/current>

*Health Policy*

#### **Envisioning environmental equity: climate change, health, and racial justice**

Thilagawathi Abi Deivanayagam, et al.

*Summary*

Climate change has a broad range of health impacts and tackling climate change could be the greatest opportunity for improving global health this century. Yet conversations on climate change and health are often incomplete, giving little attention to structural discrimination and the need for racial justice. Racism kills, and climate change kills. Together, racism and climate change interact and have disproportionate effects on the lives of minoritised people both within countries and between the Global North and the Global South. This paper has three main aims. First, to survey the literature on the unequal health impacts of climate change due to racism, xenophobia, and discrimination through a scoping review. We found that racially minoritised groups, migrants, and Indigenous communities face a disproportionate burden of illness and mortality due to climate change in different contexts. Second, this paper aims to highlight inequalities in responsibility for climate change and the effects thereof. A geographical visualisation of responsibility for climate change and projected mortality and disease risk attributable to climate change per 100 000 people in 2050 was conducted. These maps visualise the disproportionate burden of illness and mortality due to climate change faced by the Global South. Our third aim is to highlight the pathways through which climate change, discrimination, and health interact in most affected areas. Case studies, testimony, and policy analysis drawn from multidisciplinary perspectives are presented throughout the paper to elucidate these pathways. The health community must urgently examine and repair the structural discrimination that drives the unequal impacts of climate change to achieve rapid and equitable action.

### **The Lancet Child & Adolescent Health**

Jun 2023 Volume 7 Number 6 p367-440, e12

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

### **Lancet Digital Health**

Jun 2023 Volume 5 Number 6 e328-e394

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

### **Lancet Global Health**

Jun 2023 Volume 11 Number 6 e796-e981

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

### **Lancet Infectious Diseases**

Jun 2023 Volume 23 Number 6 p635-762, e198-e226  
<https://www.thelancet.com/journals/laninf/issue/current>  
[Reviewed earlier]

### **Lancet Public Health**

Jun 2023 Volume 8 Number 6 e391-e472  
<https://www.thelancet.com/journals/lanpub/issue/current>  
[New issue; No digest content identified]

### **Lancet Respiratory Medicine**

Jun 2023 Volume 11 Number 6 p493-576, e50-e60  
<https://www.thelancet.com/journals/lanres/issue/current>  
[Reviewed earlier]

### **Lancet Respiratory Medicine**

Jun 2023 Volume 11 Number 6 p493-576, e50-e60  
<https://www.thelancet.com/journals/lanres/issue/current>  
[Reviewed earlier]

### **Maternal and Child Health Journal**

Volume 27, issue 5, May 2023  
<https://link.springer.com/journal/10995/volumes-and-issues/27-5>  
[Reviewed earlier]

### **Medical Decision Making (MDM)**

Volume 43 Issue 4, May 2023  
<http://mdm.sagepub.com/content/current>  
[Reviewed earlier]

### **The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*  
Volume 101, Issue 2 Pages: 249-635 June 2023  
<https://onlinelibrary.wiley.com/toc/14680009/current>  
[New issue; No digest content identified]

### **Molecular Therapy**

Jun 07, 2023 Volume 31 Issue 6 p1501-1860  
<https://www.cell.com/molecular-therapy/current>  
***Special issue on harnessing the power of noncoding RNAs as tools and targets in gene therapy***

[Reviewed earlier]

### **Nature**

Volume 618 Issue 7966, 22 June 2023

<https://www.nature.com/nature/volumes/617/issues/7967>

[Current Issue not loading at inquiry]

### **Nature Biotechnology**

Volume 41 Issue 5, May 2023

<https://www.nature.com/nbt/volumes/41/issues/5>

[Reviewed earlier]

### **Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 01 Jul 2023)

[No new digest content identified]

### **Nature Genetics**

Volume 55 Issue 6, June 2023

<https://www.nature.com/ng/volumes/55/issues/6>

[Reviewed earlier]

### **Nature Human Behaviour**

Volume 7 Issue 6, June 2023

<https://www.nature.com/nathumbehav/volumes/7/issues/6>

[Reviewed earlier]

### **Nature Medicine**

Volume 29 Issue 6, June 2023

<https://www.nature.com/nm/volumes/29/issues/6>

[Reviewed earlier]

### **Nature Reviews Drug Discovery**

Volume 22 Issue 6, June 2023

<https://www.nature.com/nrd/volumes/22/issues/6>

[Reviewed earlier]

### **Nature Reviews Genetics**

Volume 24 Issue 6, June 2023

<https://www.nature.com/nrg/volumes/24/issues/6>

[Reviewed earlier]

### **Nature Reviews Immunology**

Volume 23 Issue 6, June 2023

<https://www.nature.com/nri/volumes/23/issues/6>

*Reviews*

#### **[CRISPR screens for functional interrogation of immunity](#)**

This Review discusses recent applications of CRISPR screening to discover intracellular and intercellular regulators of immune cell function in infection, inflammation and cancer, with a focus on the advances of in vivo and single-cell CRISPR screens in immuno-oncology.

Hao Shi, John G. Doench, Hongbo Chi

*Perspective* 25 Nov 2022

#### **[Gene therapy for inborn errors of immunity: past, present and future](#)**

In this Perspective, Alain Fischer reflects on the development of gene therapy for patients with inborn errors of immunity. He discusses the challenges the field has faced as well as the progress seen in the past 25 years.

Alain Fischer

### **Nature Reviews Immunology**

Volume 23 Issue 6, June 2023

<https://www.nature.com/nri/volumes/23/issues/6>

*Reviews*

#### **[CRISPR screens for functional interrogation of immunity](#)**

This Review discusses recent applications of CRISPR screening to discover intracellular and intercellular regulators of immune cell function in infection, inflammation and cancer, with a focus on the advances of in vivo and single-cell CRISPR screens in immuno-oncology.

Hao Shi, John G. Doench, Hongbo Chi

*Perspective* 25 Nov 2022

#### **[Gene therapy for inborn errors of immunity: past, present and future](#)**

In this Perspective, Alain Fischer reflects on the development of gene therapy for patients with inborn errors of immunity. He discusses the challenges the field has faced as well as the progress seen in the past 25 years.

Alain Fischer

### **New England Journal of Medicine**

June 29, 2023 Vol. 388 No. 26

<https://www.nejm.org/toc/nejm/medical-journal>

*Perspective*

#### **[Sharing Pathogen Genomic Sequence Data — Toward Effective Pandemic Prevention, Preparedness, and Response](#)**

S. Halabi, R. Wilder, L.O. Gostin, and M.L. Hurtado

*Original Research*

## [Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United States](#)

N.P. Deputy and Others

*Review Article*

## [AI in Medicine: Artificial Intelligence in Molecular Medicine](#)

B. Gomes and E.A. Ashley

## **njp Vaccines**

<https://www.nature.com/npjvaccines/>

[Accessed 01 Jul 2023]

## [Availability and use of Standards in vaccine development](#)

Michael Selorm Avumegah, Giada Mattiuzzo, Ingrid Kromann

Perspective Open Access 30 Jun 2023

## **Pediatrics**

Volume 151, Issue 6 June 2023

<https://publications.aap.org/pediatrics/issue/151/6>

*Article*

[Reviewed earlier]

## **PharmacoEconomics**

Volume 41, issue 7, July 2023

<https://link.springer.com/journal/40273/volumes-and-issues/41-7>

[Reviewed earlier]

## **PLoS Biology**

<https://journals.plos.org/plosbiology/>

(Accessed 01 Jul 2023)

[No new digest content identified]

## **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 01 Jul 2023)

[No new digest content identified]

## **PLOS Global Public Health**

[https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\\_NEWEST\\_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSglobalPublicHealth&q=&resultsPerPage=60](https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSglobalPublicHealth&q=&resultsPerPage=60)

(Accessed 01 Jul 2023)

## [Global health and the elite capture of decolonization: On reformism and the possibilities of alternate paths](#)

Daniel W. Krugman



Review | published 29 Jun 2023 PLOS Global Public Health  
<https://doi.org/10.1371/journal.pgph.0002103>

**[Expanding global vaccine manufacturing capacity: Strategic prioritization in small countries](#)**

Sanjana Mukherjee, Kanika Kalra, Alexandra L. Phelan  
Research Article | published 29 Jun 2023 PLOS Global Public Health  
<https://doi.org/10.1371/journal.pgph.0002098>

**[HIV policy legacies, pandemic preparedness and policy effort to address COVID-19](#)**

Ashley Fox, Heeun Kim  
Research Article | published 26 Jun 2023 PLOS Global Public Health  
<https://doi.org/10.1371/journal.pgph.0001767>

**PLoS Medicine**

<http://www.plosmedicine.org/>  
(Accessed 01 Jul 2023)  
[No new digest content identified]

**PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>  
(Accessed 01 Jul 2023)  
[No new digest content identified]

**PLoS One**

<http://www.plosone.org/>  
[Accessed 01 Jul 2023]  
**[Access, acceptability, and uptake of the COVID-19 vaccine among global migrants: A rapid review](#)**

Higinio Fernández-Sánchez, Ziad Zahoui, Jennifer Jones, Emmanuel Akwasi Marfo  
Research Article | published 30 Jun 2023 PLOS ONE  
<https://doi.org/10.1371/journal.pone.0287884>

**PLoS Pathogens**

<http://journals.plos.org/plospathogens/>  
[Accessed 01 Jul 2023]  
[No new digest content identified]

**PNAS - Proceedings of the National Academy of Sciences of the United States**

June 13, 2023 | vol. 120 | no. 24  
<https://www.pnas.org/toc/pnas/120/24>  
*Research Article* June 7, 2023 Coronavirus (COVID-19)  
**[Individual costs and societal benefits of interventions during the COVID-19 pandemic](#)**

Individual and societal reactions to an ongoing pandemic can lead to social dilemmas: In some cases, each individual is tempted to not follow an intervention, but for the whole society, it would be best if they did. Now that in most countries, the extent ...

Arne Traulsen, Simon A. Levin and Chadi M. Saad-Roy

### **PNAS Nexus**

Volume 2, Issue 6 June 2023

<https://academic.oup.com/pnasnexus/issue>

*Public Health and Epidemiology*

[Enhancing global preparedness during an ongoing pandemic from partial and noisy data](#)

Pascal P Klamser and others

PNAS Nexus, Volume 2, Issue 6, June 2023, pgad192, <https://doi.org/10.1093/pnasnexus/pgad192>

### **Prehospital & Disaster Medicine**

Volume 38 - Issue 3 - June 2023

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[New issue; No digest content identified]

### **Preventive Medicine**

Volume 170 May 2023

<https://www.sciencedirect.com/journal/preventive-medicine/vol/170/suppl/C>

[Reviewed earlier]

### **Proceedings of the Royal Society B**

28 June 2023 Volume 290 Issue 2001

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

### **Public Health**

Volume 219 Pages 1-166 (June 2023)

<https://www.sciencedirect.com/journal/public-health/vol/219/suppl/C>

[Reviewed earlier]

### **Public Health Ethics**

Volume 16, Issue 1, April 2023

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

### **Public Health Reports**

Volume 138 Issue 3, May/June 2023

<https://journals.sagepub.com/toc/phrg/138/3>

[Reviewed earlier]

### **Qualitative Health Research**

Volume 33 Issue 7, June 2023

<https://journals.sagepub.com/toc/qhra/current>

[New issue; No digest content identified]

### **Research Ethics**

Volume 19 Issue 3, July 2023

<http://journals.sagepub.com/toc/reab/current>

Original Articles

Open Access Research article First published March 23, 2023pp. 231–249

[\*\*The Harraseeket Conference – Revisiting systems for ethics oversight of research with human participants\*\*](#)

Stephen J Rosenfeld, George Shaler, Ross Hickey

Open Access Research article First published May 22, 2023pp. 341–359

[\*\*Deception and informed consent in studies with incognito simulated standardized patients: empirical experiences and a case study from South Africa\*\*](#)

Benjamin Daniels, et al.

### **Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 01 Jul 2023]

[No new digest content identified]

### **Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

*Selected Articles*

30 Jun 2023

[\*\*Factors associated with COVID-19 length of hospitalization and mortality during four epidemic waves, March 2020–November 2021, Suriname\*\*](#)

Original research | English |

### **Risk Analysis**

Volume 43, Issue 6 Pages: 1093-1295 June 2023

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

### **Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 01 Jul 2023]  
[No new digest content identified]

### **Science**

Volume 380| Issue 6652| 30 Jun 2023  
<https://www.science.org/toc/science/current>  
[New issue; No digest content identified]

### **Science and Engineering Ethics**

Volume 29, issue 3, June 2023  
<https://link.springer.com/journal/11948/volumes-and-issues/29-3>  
[Reviewed earlier]

### **Science Translational Medicine**

Volume 15| Issue 702| 28 Jun 2023  
<https://www.science.org/toc/stm/current>  
[New issue; No digest content identified]

### **Scientific Reports**

<https://www.nature.com/srep/articles?type=article>  
[Accessed 01 Jul 2023]  
[No new digest content identified]

### **Social Science & Medicine**

Volume 326 June 2023  
<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/326/suppl/C>  
[Reviewed earlier]

### **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>  
[Accessed 01 Jul 2023]  
[Reviewed earlier]

### **Theoretical Medicine and Bioethics**

Volume 44, issue 3, June 2023  
<https://link.springer.com/journal/11017/volumes-and-issues/44-3>  
[Reviewed earlier]

### **Travel Medicine and Infectious Diseases**

Volume 53 May–June 2023

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/53/suppl/C>

*Editorial Open access*

**[World tuberculosis day 2023 – Reflections on the spread of drug-resistant tuberculosis by travellers and reducing risk in forcibly displaced populations](#)**

Alfonso J. Rodriguez-Morales, Aula Abbara, Francine Ntoumi, Nathan Kapata, ... Alimuddin Zumla  
Article 102568

**Tropical Medicine & International Health**

Volume 28, Issue 6 Pages: i-iv, 419-506 June 2023

<https://onlinelibrary.wiley.com/toc/13653156/current>

*REVIEWS*

*Open Access*

**[Lassa fever vaccine candidates: A scoping review of vaccine clinical trials](#)**

Giorgia Sulis, Alexandra Peebles, Nicole E. Basta

Pages: 420-431

First Published: 24 April 2023

**Vaccine**

Volume 41, Issue 23 Pages 3473-3578 (26 May 2023)

<https://www.sciencedirect.com/journal/vaccine/vol/41/issue/23>

*Selected Content*

*Discussion*

**[Serious adverse events following mRNA vaccination in randomized trials in adults](#)**

Steven Black, Stephen Evans

Pages 3473-3474

*Short communication Full text access*

**[COVID-19 vaccine deliberation in individuals directly impacted by incarceration](#)**

Charlotte Kim, Jenerius A. Aminawung, Lauren Brinkley-Rubinstein, Emily A. Wang, Lisa B. Puglisi

Pages 3475-3480

*Research article Open access*

**[Sustained antibody persistence for at least 15 years after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules: Third 5-year follow-up](#)**

Jiří Beran, Maria Lattanzi, Marco Costantini, Andrea Pammolli, Ilaria Galgani

Pages 3518-3524

*Research article Open access*

**[Development of a COVID-19 vaccine effectiveness and safety assessment system in Japan: The VENUS study](#)**

Haruhisa Fukuda, Megumi Maeda, Fumiko Murata

Pages 3556-3563

**Vaccines**

<https://www.mdpi.com/journal/vaccines>

[Accessed 01 Jul 2023]

*Latest Articles*

*Open Access Article*

**[The Trajectory of Brazilian Immunization Program between 1980 and 2018: From the Virtuous Cycle to the Vaccine Coverage Decline](#)**

by [Marcia Michie Minakawa](#)<sup>1,\*</sup> and [Paulo Frazão](#)

Vaccines 2023, 11(7), 1189; <https://doi.org/10.3390/vaccines11071189> (registering DOI)

*Open Access Article*

**[Knowledge, Perception, and Acceptance of HPV Vaccination and Screening for Cervical Cancer among Saudi Females: A Cross-Sectional Study](#)**

by [Khulud Ahmad Rezq](#), et al.

Vaccines 2023, 11(7), 1188; <https://doi.org/10.3390/vaccines11071188> (registering DOI)

Received: 23 May 2023 / Revised: 20 June 2023 / Accepted: 28 June 2023 / Published: 1 July 2023

**Value in Health**

June 2023 Volume 26 Issue 6 p791-956

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

.....  
.....

***Contents [click to move among sections]***

:: [Coronavirus \[COVID-19\]](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....  
.....

**[Pre-Print Servers](#)**

**Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 01 Jul 2023]

*Selected Research*

[No new digest content identified]

**medRxiv**

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 01 Jul 2023]

*[Filter: All articles]*

*Selected Research*

## [Vaccines at Velocity: Evaluating Potential Lives Saved by Earlier Vaccination in the COVID-19 Pandemic](#)

Witold Wiecek, David Johnston, Tomas Dulka, Danny Toomey, Enlli Lewis  
medRxiv 2023.06.16.23291442; doi: <https://doi.org/10.1101/2023.06.16.23291442> Revision

### *Abstract*

Fast development of COVID-19 vaccines likely averted millions of deaths. We estimate how many more lives could have been saved if safe and effective vaccines were available earlier in the pandemic, in particular, before the epidemic waves in winter of 2020. We fit an epidemiological model informed by retrospective data and simulate counterfactual vaccination scenarios for the United Kingdom and the United States in which vaccines are available between 30 and 90 days earlier. We find that up to 1 July 2021 reductions in mortality range from 10,000 to 48,000 in the UK and 53,000 to 130,000 in the US, depending on when vaccinations start. This corresponds to a maximum of 7.1 and 4 deaths averted per 10,000 people in the UK and US respectively. We find that our model is sensitive to uncertain vaccine parameters and benefits depend on the time horizon of the analysis. However, the large average reductions we estimate suggests that it is highly cost-effective to make large investments in strategies to expedite vaccine availability.

## [Diversity and Scale: Genetic Architecture of 2,068 Traits in the VA Million Veteran Program](#)

Anurag Verma, Jennifer E Huffman, Alex Rodriguez, Mitchell Conery, Molei Liu, Yuk-Lam Ho, Youngdae Kim, David A Heise, Lindsay Guare, Vidul Ayakulangara Panickan, Helene Garcon, Franciel Linares, Lauren Costa, Ian Goethert, Ryan Tipton, Jacqueline Honerlaw, Laura Davies, Stacey Whitbourne, Jeremy Cohen, Daniel C Posner, Rahul Sangar, Michael Murray, Xuan Wang, Daniel R Dochtermann, Poornima Devineni, Yunling Shi, Tarak Nath Nandi, Themistocles L Assimes, Charles A Brunette, Robert J Carroll, Royce Clifford, Scott Duvall, Joel Gelernter, Adriana Hung, Sudha K Iyengar, Jacob Joseph, Rachel Kember, Henry Kranzler, Daniel Levey, Shiuuh-Wen Luoh, Victoria C Merritt, Cassie Overstreet, Joseph D Deak, Struan F A Grant, Renato Polimanti, Panos Roussos, Yan V Sun, Sanan Venkatesh, Georgios Voloudakis, Amy Justice, Edmon Begoli, Rachel Ramoni, Georgia Tourassi, Saiju Pyarajan, Philip S Tsao, Christopher J O'Donnell, Sumitra Muralidhar, Jennifer Moser, Juan P Casas, Alexander G Bick, Wei Zhou, Tianxi Cai, Benjamin F Voight, Kelly Cho, Michael J Gaziano, Ravi K Madduri, Scott M Damrauer, Katherine P Liao

medRxiv 2023.06.28.23291975; doi: <https://doi.org/10.1101/2023.06.28.23291975>

## [Targeting hepatitis B vaccine escape using immunogenetics in Bangladeshi infants](#)

Guillaume Butler-Laporte, Kathryn Auckland, Zannatun Noor, Mamun Kabir, Masud Alam, Tommy Carstensen, Genevieve L Wojcik, Amanda Y Chong, Cristina Pomilla, Janelle A Noble, Shana McDevitt, Gaby Smits, Susan Wareing, Fiona RM van der Klis, Katie Jeffery, Beth Kirkpatrick, Sodiomon Sirima, Shabir Madhi, Alison Elliott, J Brent Richards, Adrian VS Hill, Priya Duggal, PROVIDE authors, CRYPTO authors, Manjinder S Sandhu, Rashidul Haque, William A Petri Jr., Alexander J Mentzer

medRxiv 2023.06.26.23291885; doi: <https://doi.org/10.1101/2023.06.26.23291885>

### **OSF Pre-prints**

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Accessed 01 Jul 2023]

*[Provider Filter: OSF Pre-prints Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]*

***We observe increasing levels of "posting pollution" by individuals, sometimes posting 10+ items of no value. If this continues, we may decide to no longer monitor this resource.***

[We are temporarily suspending active coverage of this resource due to “posting pollution”]

### **Wellcome Open Research**

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 01 Jul 2023]

*Selected Research*

*Research Article Open Access*

**[REVISED - Environmental sampling for SARS-CoV-2 in long term care facilities: lessons from a pilot study](#)** [version 2; peer review: 1 not approved]

Rachel wiatkowska, et al.

*Abstract*

Background: The SARS-CoV-2 pandemic has highlighted the risk of infection in long-term care facilities (LTCF) and the vulnerability of residents to severe outcomes. Environmental surveillance may help detect pathogens early and inform Infection Prevention and Control (IPC) measures in these settings.

\* \* \* \*

### **Think Tanks**

**Brookings** [to 01 Jul 2023]

<http://www.brookings.edu/>

*Latest Research [Selected]*

*No new digest content identified.*

**Center for Global Development** [to 01 Jul 2023]

<https://www.cgdev.org/>

*All Research [Selected]*

*No new digest content identified.*

**Chatham House** [to 01 Jul 2023]

<https://www.chathamhouse.org/>

*Selected Analysis, Comment, Events*

*No new digest content identified.*

**CSIS** [to 01 Jul 2023]

<https://www.csis.org/>

*Selected Reports, Events*

**[The EU Data Act: The Long Arm of European Tech Regulation Continues](#)**

The EU Data Act, along with imposing significant regulatory costs for U.S. companies by discriminating against large digital services providers, will also pose a heavy burden on European economic growth.

Report by Meredith Broadbent — June 29, 2023



**Kaiser Family Foundation** [to 01 Jul 2023]

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

*Newsroom*

**[Medicaid Expansion Has Had Beneficial Effects on Some Sexual and Reproductive Health Outcomes](#)**

June 29, 2023 News Release

A new KFF review of more than three dozen studies published between April 2021 and June 2023 finds that Medicaid expansion under the Affordable Care Act is associated with beneficial effects on a range of sexual and reproductive health outcomes. The studies, which echo findings of previous research, find that...

**McKinsey Global Institute** [to 01 Jul 2023]

<https://www.mckinsey.com/mgi/overview>

*Latest Research*

*No new digest content identified.*

**ODI [Overseas Development Institute]** [to 01 Jul 2023]

<https://odi.org/en/publications/>

*Publications [Selected]*

**[Beyond survival: exploring wellbeing in humanitarian action](#)**

26 June 2023

*Literature reviews*

**Pew Research Center** [to 01 Jul 2023]

<https://www.pewresearch.org/>

*Latest Publications [Selected]*

*No new digest content identified.*

**Rand** [to 01 Jul 2023]

<https://www.rand.org/pubs.html>

*Published Research [Selected]*

*Journal Article*

**[Artificial Intelligence in the COVID-19 Response: Volume 2, Strategies to Improve the Impact of AI on Health Equity](#)**

This report examines the use of artificial intelligence (AI) in the COVID-19 pandemic response and describes 66 AI applications — specific products or tools — used in clinical care and 54 AI applications used to inform public health decision-making.

Jun 22, 2023

Sean Mann, Lawrence Baker, Federico Girosi, Osonde A. Osoba, Carl Berdahl

**Urban Institute** [to 01 Jul 2023]

<https://www.urban.org/publications>

## New Research Publications - Selected

*No new digest content identified.*

### **World Economic Forum** [to 01 Jul 2023]

<https://agenda.weforum.org/news/>

*Media*

### **Asia's Generative AI Experts Call for Guardrails and Responsible Design**

News 28 Jun 2023

- Biggest concerns with AI are bias, user competency, transparency and predictability.
- In all critical fields, the decision-making power must rest with a human and education on AI is key.
- To ensure a positive future, it is crucial to prioritize responsible design and release practices from the beginning.
- Watch the session at [wef.ch/amnc23](http://wef.ch/amnc23) and follow using #amnc23 or #2023夏季达沃斯# on Weibo and WeChat.

### **Gender Equality Is Stalling: 131 Years to Close the Gap**

News 20 Jun 2023

\* \* \* \* \*  
\* \* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

*Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.*

*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

.....

CVEP is a program of the [GE2P2 Global Foundation](http://www.ge2p2.org/) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

\* \* \* \* \*  
\* \* \* \* \*